James Love on India bashing at USTR’s Feb 24, 2014 Special 301 hearing
Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.
Continue Reading
Author: KEI Staff
2014, PhRMA discussion of India
PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country citing the fact that India “continues to embrace these damaging policies, especially its IP rules, by publicly highlighting them… Continue Reading
2014, NFTC discussion of India
The National Foreign Trade Council (NFTC) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India as a Priority Foreign Country and “conduct an out-of-cycle review of India to assess” Indian policies “across sectors,… Continue Reading
2014, NAM discussion of India
The National Association of Manufacturers’s (NAM) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests that USTR designate India as a Priority Foreign Country citing concerns with India’s actions in multilateral fora including the UNFCCC, WTO and… Continue Reading
2014, IPO discussion of India
The Intellectual Property Owners Association’s (IPO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review expressed concern over various aspects of India’s policies including “India’s Forced Technology Transfer, Compulsory Licensing, and Lack of Effective IP Protection” and “Third… Continue Reading
2014, BIO discussion of India
The Biotechnology Industry Organization (BIO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India a Priority Foreign Country. BIO expressed concerns over the robust use of patent oppositions in India: The Indian generic… Continue Reading
Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading
29 Organizations and More than 70 Individuals Sign Letter Opposing Life Plus Seventy Year Copyright Term in TPP
29 organizations and more than 70 individuals signed on to the final letter opposing copyright terms of life plus seventy years in the Trans-Pacific Partnership Agreement (TPP). A PDF version of the final letter is attached below. An earlier version of the letter with a substantial number of signatures was sent to all lead IP negotiators and all chief negotiators in the TPP on Friday, 6 December 2013, in advance of the TPP ministerial.